ProCE Banner Activity

FAQs on the Use of BCMA-Targeted Therapies for Relapsed or Refractory Multiple Myeloma

Clinical Thought
Experts answer frequently asked questions on the management of relapsed or refractory multiple myeloma with BCMA-targeted agents.

Released: October 29, 2021

Expiration: October 28, 2022

No longer available for credit.

Share

Faculty

Sagar Lonial

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Suzanne Lentzsch

Suzanne Lentzsch, MD, PhD

Director, Multiple Myeloma and Amyloidosis Program
Associate Professor of Medicine
Division of Hematology/Oncology
Columbia University Medical Center
New York, New York

Thomas G. Martin

Thomas G. Martin, MD

Associate Clinical Professor of Medicine
Associate Director
, Myeloma Institute
University of California, San Francisco Medical Center
San Francisco, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

GlaxoSmithKline

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Program Director Disclosure

Program Director

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Sagar Lonial, MD, has disclosed that he has received funds for research support from Bristol-Myers Squibb, Celgene, Janssen, and Takeda; consulting fees from AbbVie, Bluebird, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, and Takeda; and other financial or material support from TG Therapeutics.

Faculty Disclosure

Primary Author

Suzanne Lentzsch, MD, PhD

Director, Multiple Myeloma and Amyloidosis Program
Associate Professor of Medicine
Division of Hematology/Oncology
Columbia University Medical Center
New York, New York

Suzanne Lentzsch, MD, PhD, has disclosed that she has received consulting fees from AbbVie, Caelum, Celularity, GlaxoSmithKline, Janssen, Karyopharm, Sanofi, Sorrento, and Takeda; has received funds for research support from Karyopharm and Sanofi; has ownership interest in Caelum; and has received salary from Magenta.

Thomas G. Martin, MD

Associate Clinical Professor of Medicine
Associate Director
, Myeloma Institute
University of California, San Francisco Medical Center
San Francisco, California

Thomas G. Martin, MD, has disclosed that he has received funds for research support from Amgen, Johnson & Johnson/Janssen, Sanofi, and Seattle Genetics.

Staff Disclosure

Staff

Tanja Link, PhD

Editorial Contributor

Tanja Link, PhD, has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.